You know, this was a a shield, you know, one of the guys, he doesn't make a appearance, but he's, know, who he is
Anazco and Acosta [147] argue that the expanding range of pharmacological options will push the field toward personalized treatment matchingselecting interventions based on both biological and psychological patient profiles rather than on general efficacy alone
Herein, we provide perspectives on the historical events and key experimental findings establishing the biology of GLP-1 as an insulin-stimulating glucoregulatory hormone
Jimnez, N
What's the difference between semaglutide and tirzepatide, and which should I choose
3 Result 3.1 Procedure and outcomes of included literature 2008 literatures were initially screened in the database according to keywords, and 176 were obtained after de-duplication and exclusion of review literature, irrelevant literature, incomplete data, unreported cardiovascular events, unspecified results, and incorrect study type, and then 8 clinical trials with a total of 68,001 patients were finally included after the screening process was repeated by two investigators again ( Figure 1 )
